(Q34127007)

English

Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

31 July 2017

Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT. (English)

1 reference

Europe PubMed Central

31 July 2017

phosphorylation

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

author name string

Christopher R Garrett

1

1 reference

Europe PubMed Central

31 July 2017

Domenico Coppola

2

1 reference

Europe PubMed Central

31 July 2017

Robert M Wenham

3

1 reference

Europe PubMed Central

31 July 2017

Christopher L Cubitt

4

1 reference

Europe PubMed Central

31 July 2017

Anthony M Neuger

5

1 reference

Europe PubMed Central

31 July 2017

Timothy J Frost

6

1 reference

Europe PubMed Central

31 July 2017

Richard M Lush

7

1 reference

Europe PubMed Central

31 July 2017

Daniel M Sullivan

8

1 reference

Europe PubMed Central

31 July 2017

Jin Q Cheng

9

1 reference

Europe PubMed Central

31 July 2017

Saïd M Sebti

10

1 reference

Europe PubMed Central

31 July 2017

publication date

20 July 2010

1 reference

Europe PubMed Central

31 July 2017

Investigational New Drugs

1 reference

Europe PubMed Central

31 July 2017

29

1 reference

Europe PubMed Central

31 July 2017

1381-1389

1 reference

Europe PubMed Central

31 July 2017

6

1 reference

Europe PubMed Central

31 July 2017

https://scigraph.springernature.com/pub.10.1007/s10637-010-9479-2

0 references

The PI3K/Akt pathway: recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4612514

5 July 2018

Exploiting the PI3K/AKT pathway for cancer drug discovery

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4612514

5 July 2018

Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4612514

5 July 2018

Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4612514

5 July 2018

AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4612514

5 July 2018

Cellular survival: a play in three Akts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4612514

5 July 2018

Transforming activity and mitosis-related expression of the AKT2 oncogene: evidence suggesting a link between cell cycle regulation and oncogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4612514

5 July 2018

A phase II trial of tricyclic nucleoside phosphate in patients with advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4612514

5 July 2018

Phase I study of tricyclic nucleoside phosphate using a five-day continuous infusion schedule

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4612514

5 July 2018

Phase I evaluation and clinical pharmacology of tricyclic nucleoside 5'-phosphate using a weekly intravenous regimen.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4612514

5 July 2018

A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4612514

5 July 2018

The synthesis of 6-amino-4-methyl-8-(β-D-ribofuranosyl) (4-H,8-H)pyrrolo-[4,3,2-de]pyrimido[4,5-c]pyridazine, a new tricyclic nucleoside

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9479-2

21 January 2018

A Phase II Trial of Tricyclic Nucleoside Phosphate in Patients with Advanced Squamous Cell Carcinoma of the Cervix

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9479-2

21 January 2018

Phase I-II study: triciribine (tricyclic nucleoside phosphate) for metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9479-2

21 January 2018

A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9479-2

21 January 2018

A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9479-2

21 January 2018

The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9479-2

21 January 2018

Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9479-2

21 January 2018

Will kinase inhibitors have a dark side?

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9479-2

21 January 2018

A rational approach to personalized anticancer therapy: chemoinformatic analysis reveals mechanistic gene-drug associations.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9479-2

21 January 2018

Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/20644979

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II clinical trial of tricyclic nucleoside phosphate for advanced colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20644979

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of tricyclic nucleoside phosphate

1 reference

https://pubmed.ncbi.nlm.nih.gov/20644979

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Disposition of tricyclic nucleoside-5'-monophosphate in blood and plasma of patients during phase I and II clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/20644979

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-010-9479-2

1 reference

Europe PubMed Central

31 July 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

31 July 2017

1 reference

Europe PubMed Central

31 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34127007&oldid=2143852618"